A Month After Lung Cancer Withdrawal, Takeda Gets Approval For New Colorectal Cancer Drug

The US FDA approved Fruzaqla (fruquintinib) for previously treated metastatic disease regardless of biomarker status. The drug, already approved in China, was de-risked when Takeda licensed it from HutchMed.